etd Ege Tıp Dergisi 1016-9113 2147-6500 Ege Üniversitesi 10.19161/etd.502958 Health Care Administration Sağlık Kurumları Yönetimi Seroprevalence of HBsAg and anti-HCV for patients who admitted to third step hospital: Six-year retrospective data Üçüncü basamak bir hastaneye başvuran hastalarda HBsAg ve anti-HCV seroprevalansı: Altı yıllık retrospektif veriler https://orcid.org/0000-0002-7505-341X Bayırlı Turan Derya İstanbul Yeni Yüzyıl University School of Medicine, Gaziosmanpaşa Hospital, Department of Infectious Diseases and Clinical Microbiology, İstanbul https://orcid.org/0000-0003-3805-367X Kuruoğlu Tuba Ondokuz Mayıs University School of Medicine, Department of Infectious Diseases and Clinical Microbiology, Samsun https://orcid.org/0000-0003-4070-6924 Gümüş Defne İstanbul Yeni Yüzyıl University School of Medicine, Department of Medical Microbiology and Clinical Microbiology, İstanbu https://orcid.org/0000-0002-0028-5646 Kalaycı Fatma İstanbul Yeni Yüzyıl University School of Medicine, Department of Medical Microbiology and Clinical Microbiology, İstanbu https://orcid.org/0000-0003-0585-8797 Şerefhanoğlu Kıvanç İstanbul Yeni Yüzyıl University School of Medicine, Gaziosmanpaşa Hospital, Department of Infectious Diseases and Clinical Microbiology, İstanbul 06 28 2019 58 2 149 153 03 02 2018 05 25 2018 Copyright © 1962, Ege Tıp Dergisi 1962 Ege Tıp Dergisi

Aim: We aimed to investigate the alteration and distribution of seroprevalence of hepatitis B and hepatitis C withinthe years according to age groups in patients who applied to our hospital.Materials and Methods: The patients have been evaluated for six years retrospectively who were admitted to thirdstep hospital in Istanbul. The duplicate results of patients who submitted more than one application within the sameyear were excluded from this study. Male and female patients were divided into four age groups as 0-14, 14-25, 25-49 and over 49 years old. Electrochemiluminescence method (Roche Cobas 6000, Germany) was used for HBsAgand anti-HCV assays.Results: HBsAg positivity was 2.97% and anti-HCV positivity was 1.35%. HBsAg positivity was higher in males, andanti-HCV positivity was higher in females. No significant increase in seroprevalences of anti-HCV and HBsAg wasobserved during the six years observation period. HBsAg seroprevalences decreased in years especially in 0-14 and14-25 year-old male groups. HBsAg seroprevalence was not decreased in the other age groups over the years.There was no significant difference in anti-HCV seroprevalence over the years. HBsAg positivity was higher in malesand anti-HCV positivity was higher in females. Anti-HCV and HBsAg seroprevalence were not significantly differedover the years.Conclusion: It was remarkable that HBsAg positivity rate had decreased over the years especially in 0-14 and 14-25year-old males. Seroprevalence of HBsAg did not decrease in years in other age groups. There was no significantdifference in the seroprevalence of anti-HCV during the measurement period.

Amaç: Çalışmamızda hastanemize başvuran hastalarda Hepatit B ve Hepatit C seroprevalansının yaş gruplarınagöre yıllar içindeki değişimini ve dağılımını araştırmayı amaçladık.Gereç ve Yöntem: İstanbul'da üçüncü basamak hastaneye altı yıl boyunca başvuran hastalar retrospektif olarakdeğerlendirildi. Aynı yıl içinde birden fazla başvuru yapan hastaların mükerrer sonuçları çalışma dışı bırakıldı. Kadınve erkek hastalar 0-14, 14-25, 25-49 ve 49 yaş üzeri olmak üzere dört yaş grubuna ayrıldı. HBsAg ve anti-HCVtestleri için elektrokemilüminesans yöntemi (Roche Cobas 6000, Almanya) kullanıldı.Bulgular: HBsAg pozitifliği %2,97 ve anti-HCV pozitifliği %1,35 oranında saptandı. HBsAg pozitifliği erkeklerde, antiHCV pozitifliği kadınlarda daha yüksek oranda idi. Anti-HCV ve HBsAg seroprevalansında 6 yıllık periyodda dikkatiçekecek artış saptanmadı. HBsAg seroprevalansında özellikle 0-14 ve 14-25 yaş erkek gruplarında yıllar içindeazalma dikkati çekti. Diğer yaş gruplarında HBsAg seroprevalansında yıllar içinde bir azalma saptanmadı. Anti-HCVseroprevalansında ise yıllar içinde dikkati çekecek önemli bir fark saptanmadı.Sonuç: HBsAg pozitifliğinde özellikle 0-14 ve 14-25 yaş erkek gruplarında yıllar içinde azalma dikkati çekti. Diğer yaşgruplarında HBsAg seroprevalansında yıllar içinde bir azalma saptanmadı. Anti-HCV seroprevalansında ise yıllariçinde dikkati çekecek önemli bir fark saptanmadı.

 Anti-HCV HBsAg seroprevalence age distribution Anti-HCV HBsAg seroprevalans yaş dağılımı. You CR, Lee SW, Jang JW, Yoon S K. Update on hepatitis B virus infection. World J Gastroenterol 2014;20(37):13293-305. Zampino R, Boemio A, Sagnelli C, et al. Hepatitis B virus burden in developing countries. World J Gastroenterol 2015;21(42):11941-53. Caccamo G, Saffioti F, Raimondo G. Hepatitis B virus and hepatitis C virus dual infection. World J Gastroenterol 2014;28:20(40):14559-67. WHO Hepatitis B. Available from: http://www.who.int/news-room/fact-sheets/detail/hepatitis-b. Ergunay K, Balaban Y, Cosgun E, Hascelik G. Epidemiological trends in HBV infections at a reference centre in Turkey: An 11-year retrospective analysis. Ann Hepatol 2012;11(5):672-8. WHO Hepatitis C. Available from: http://www.who.int/news-room/fact-sheets/detail/hepatitis-c. Akarca US. Chronic hepatitis B. A guideline to diagnosis, approach, management, and follow‐up 2007. Turkish Association for the Study of Liver. Turk J Gastroenterol 2008;19(4):207‐30. Shepard CW, Simard EP, Finelli L, Fiore AE, Bell BP. Hepatitis B virus infection: Epidemiology and vaccination. Epidemiol Rev 2006;28(1):112-25. Iqbal K, Klevens RM, Kainer MA, et al. Epidemiology of acute hepatitis B in the United States from population-based surveillance, 2006-2011. Clin Infect Dis 2015;61(4):584-92. Toy M, Önder FO, Wörmann T, et al. Age- and region-specific hepatitis B prevalence in Turkey estimated using generalized linear mixed models: A systematic review. BMC Infect Dis 2011;11(2):337. Alam MM, Zaidi SZ, et al. Molecular epidemiology of hepatitis B virus genotypes in Pakistan. BMC Infect Dis 2007;7(1):115. WHO Hepatitis. Available from: http://www.who.int/ mediacentre /factsheets/ fs204 Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: New estimates of age-specific antibody to HCV seroprevalence. Hepatology 2013;57(4):1333-42. Lee MH, Yang HI, Yuan Y, L'Italien G, Chen CJ. Epidemiology and natural history of hepatitis C virus infection. World J Gastroenterol 2014;28(20):9270-80. Niu Z, Zhang PA,Tong YQ. Age and gender distribution of hepatitis C virus prevalence and genotypes of individuals of physical examination in Wu Han, Central China. Springer Plus 2016;13(5):1557. Gower E, Estes C, Blach S, Razavi-Shearer K, Razavi H. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol 2014;61(1):45-57. Ni YH, Huang LM, Chang MH, et al. Two decades of universal hepatitis B vaccination in Taiwan: Impact and Implication for future strategies. Gastroenterology 2007;132(4):1287-93. Liang X, Bi S, Yang W, et al. Epidemiological serosurvey of hepatitis B in China-declining HBV prevalence due to hepatitis B vaccination. Vaccine 2009;27(47):6550-7. Turhanoğlu M, Onur A, Bilman FB, Ayaydın Z, Aktar GS. Eight-year seroprevalence of HBV, HCV and HIV in Diyarbakir Training and Research Hospital. Int J Med Sci 2013;12:10(11):1595-601. Pépin J, Lavoie M, Pybus OG, et al. Risk factors for hepatitis C virus transmission in colonial Cameroon. Clin Infect Dis 2010;51(7):768-76. Westbrook RH, Dusheiko. Natural history of hepatitis. C J Hepatol 2014;61(1):58-68. Yapalı S. Seroprevalance of hepatitis B and C infections in Turkey. Turk J Gastroenterol 2017;28(2):147-8. Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 2006;144(10):705-14. Rantala M, van de Laar MJ. Surveillance and epidemiology of hepatitis B and C in Europe-a review. Euro Surveill 2008;13(21):18880. Baden R, Rockstroh JK, Buti M. Natural history and management of hepatitis C: Does sex play a role? J Infect Dis 2014;15;209(3):81-5. Galani BRT, Njouom R, Moundipa PF. Hepatitis C in Cameroon: What is the progress from 2001 to 2016? J Transl Int Med 2016;1(4):162-9.